Angiotensin II receptor blockade and skeletal muscle metabolism in overweight and obese adults with elevated blood pressure.

What Was Tested

This clinical trial looks at Angiotensin II Type 1 Receptor Blockers in the context of low blood pressure and orthostatic hypotension.

Who Took Part

The abstract describes 12 individuals taking part.

The age groups tagged for this paper are teenagers, young adults, adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

In design terms this was a placebo-controlled and crossover study.

A placebo (an inactive look-alike) gave the Angiotensin II Type 1 Receptor Blockers group a baseline to be compared against.

In the crossover set-up each of the individuals took both Angiotensin II Type 1 Receptor Blockers and the comparison in turn, acting as their own control.

Fatty acid oxidation was measured before and after each intervention by counting the (14)CO2 produced from [1-(14)C] palmitic acid in skeletal muscle homogenates.

What Was Measured

Topics PubMed links to this paper include Angiotensin II Type 1 Receptor Blockers, Body Mass Index, Fatty Acids, Hypertension, Imidazoles, Muscle, Skeletal and Obesity.

The authors tagged it with the keywords angiotensin II receptor blockade and skeletal muscle metabolism.

What This Means in Plain Language

The paper is a placebo-controlled and crossover study of Angiotensin II Type 1 Receptor Blockers in 12 individuals in people with low blood pressure and orthostatic hypotension.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2015 (Therapeutic advances in cardiovascular disease), a journal based in England.

More context: Low blood pressure and orthostatic hypotension research.